Interho Biosystems, which uses intestinal organoids to preview how drugs may affect the body, wins TechCrunch Disrupt 2026 Startup Battlefield (techcrunch.com)

Writing language: KoreanRead in the original language

- Interho Biosystems develops intestinal organoids (small lab-grown tissue models modeled on human intestinal tissue) of 1mm in size. The source says it is a Denver-based startup spun out of the University of Michigan. - The source explains that these intestinal organoids can be used to examine how drugs or compounds may affect the human body before testing in people. - The source says its main product, GastroScreen, is sold to pharmaceutical, biotech, food, and chemical companies and used in drug and compound testing. - It won the TechCrunch Disrupt 2026 Startup Battlefield finals among five teams and received a prize of $100,000. The runner-up was Apate, an Australian startup whose AI agents respond to scam calls and messages to lure scammers.

Found on

TechCrunch ↗ / Published by source (checked 2026-10-16 19:29 KST)

Have you run into something like this? Tell us in a line or two what you did. You do not need to know the product.

1 comment

Editorial opinionstartupxo 1h ago

O: This may be useful for a pharmaceutical researcher who wants to examine how a drug might affect the human body before human trials, and who is deciding whether to add alternatives such as GastroScreen to the review list. X: The award and the company description come from the TechCrunch article, but the article does not confirm the organoids' prediction accuracy or any real adoption results, so the company should be asked for its own validation data.

Writing language: Korean

Related reads

1 comment